Three-dimensional (3D) printing has recently appeared as one of the most promising additive manufacturing techniques to fabricate 3D objects, with uses spanning from engineering prototyping to medicines and cell-laden models for biomedical applications. Regardless of the type and underlying theory, 3D printing techniques involve the deposition of materials such as thermoplastic polymers or hydrogel in sequential layers one onto another to produce a 3D object. 3D printing has recently gained momentum in developing various drug delivery systems for pharmaceutical applications which is reflected by the exponential rise in the number of published papers and patents in recent years. Whilst the future of 3D printing techniques is bright, various obstacles need to be overcome before it can be applied practically in commercial-scale production. This review article discusses current approaches of altering drug delivery when manufacturing 3D printed dosage forms that vary in their drug release profiles and characteristics. Such achievements correspond to developing and delivering patient-specific treatments. With each type of 3D printing application, there are great benefits, and these are highlighted, however, a critical discussion will underline the limitations and challenges associated with 3D printing.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/03639045.2020.1801714 | DOI Listing |
J Cardiothorac Surg
January 2025
Semmelweis University Heart and Vascular Centre, Budapest, 1122, Hungary.
Background: Aortic dissection occurs rarely during pregnancy but carries a significantly high vital risk for both the mother and the fetus. Early diagnosis and treatment are critical for a successful outcome.
Case Presentation: A 32-year-old pregnant woman at 31 weeks of gestation began experiencing shortness of breath, chest pain, and palpitations, which were attributed to an anxiety disorder she had been previously diagnosed with.
Isr J Health Policy Res
January 2025
Geha Mental Health Center, Helsinki 1st, Petach-Tikva, +9729258220, Israel.
Background: The events of October 7, 2023, and the subsequent war have starkly exposed the shortcoming of Israel's public mental health system. This system, already strained by years of underfunding and the COVID-19 pandemic, was unprepared for the surge in mental health needs resulting from these traumatic events. This paper outlines the systemic failures and proposes a comprehensive overhaul reform towards an integrative community-based, recovery-oriented mental health service.
View Article and Find Full Text PDFBMC Pediatr
January 2025
Institute of Pediatric Endocrinology, Dana Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
Background: The diagnosis of depression or anxiety treated by SSRIs has become relatively common in women of childbearing age. However, the impact of gestational SSRI treatment on newborn thyroid function is lacking. We explored the impact of gestational SSRI treatment on newborn thyroid function as measured by the National Newborn Screening (NBS) Program and identified contributory factors.
View Article and Find Full Text PDFDrug Deliv Transl Res
January 2025
Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Atherosclerosis (AS) is a chronic inflammatory disease characterized by vascular endothelial dysfunction. In the early stage of the disease, endothelial cell injury induces the infiltration of inflammatory macrophages, which secrete large amounts of inflammatory factors, further aggravating endothelial cell dysfunction and exacerbating the disease. Therefore, it is promising for co-targeting endothelial cells and macrophages further regulating the inflammatory microenvironment and endothelial cell function for effective treatment.
View Article and Find Full Text PDFEur J Drug Metab Pharmacokinet
January 2025
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Background And Objective: A gonadotropin-releasing hormone (GnRH) agonist such as leuprolide is widely used to achieve sustained suppression of testosterone levels, which play a critical role in the treatment of prostate cancer. Recent advances in drug delivery systems have led to the development of long-acting depot formulations, such as the 6-month intramuscular (IM) leuprolide formulation, which aim to simplify dosing and improve convenience for both patients and healthcare providers. Exploring extended dosing intervals for such formulations represents a promising approach to further optimize treatment regimens, potentially balancing efficacy with patient-centered care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!